Now that April has arrived and baseball season is back in gear, the market responded by putting on its rally cap on Monday. U.S. equities rose broadly with all three of the major indices seeing over a 1% gain. The S&P 500 climbed 1.16% (32.79 points) while the Nasdaq shot up 1.29% (99.59 points). The Dow rose throughout the day before ending the session up 1.27% (329.74 points).
Although a few of the individual components of the Dow had to put up with losses today, the majority of them saw substantial gains. Caterpillar (CAT) led the pack as it soared 3.51%. JPMorgan (JPM) also did quite well, notching gains of 3.37% by the time the market closed. United Technologies (UTX) was right up there with them, as it increased by 3.34%. The 52-week trading range in
Outside the index, Atossa Genetics (ATOS) also saw gains today as the Seattle-based biopharmaceutical company rose 1.70% to end Monday’s session at $3.58/share. The 52-week trading range is $.80 – $7.39. The average daily 3-month volume is now 3.23 million shares per day.
INVO Bioscience (IVOB) is a Medford, MA-based medical device company focused on creating simplified treatments for patients diagnosed with infertility. Their lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). INVO shares closed trading today at $.40/share.
Stocks rose today on the heels of the results of China’s Caixin/Markit Manufacturing PMI helped to calm investors fears of global slowdown. The new data showed that the index came in at 50.8 in March meaning that the manufacturing sector in China has finally made it out of the contractionary territory and is expanding once again. This marks the first expansionary result in four months and it is the fastest growth in eight.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!